A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease

Therapeutic options for Alzheimer’s disease, the most common form of dementia, are currently restricted to palliative treatments. The glycosaminoglycan heparin, widely used as a clinical anticoagulant, has previously been shown to inhibit the Alzheimer’s disease-relevant β-secretase 1 (BACE1). Despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mycroft-West, Courtney J., Cooper, Lynsay C., Devlin, Anthony J., Procter, Patricia, Guimond, Scott E., Guerrini, Marco, Fernig, David G., Lima, Marcelo A., Yates, Edwin A., Skidmore, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562973/
https://www.ncbi.nlm.nih.gov/pubmed/31100859
http://dx.doi.org/10.3390/md17050293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562973/
https://www.ncbi.nlm.nih.gov/pubmed/31100859
http://dx.doi.org/10.3390/md17050293

Ejemplares similares